Backabrdn Life Sciences Investors Overview

abrdn Life Sciences Investors Long Term Debt

Latest long-term debt for HQL: $0.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$0.00

Peer trimmed avg / median

Loading

abrdn Life Sciences Investors Long Term Debt History

Loading

abrdn Life Sciences Investors vs. peers: Long Term Debt Comparison

Loading

abrdn Life Sciences Investors Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

abrdn Life Sciences Investors (HQL) FAQ

abrdn Life Sciences Investors's long-term debt stands at $0 as of March 2026. In the prior-year period, the figure was $0. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

abrdn Life Sciences Investors reported $0 in long-term debt versus $0 a year earlier. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

In the prior-year period, the figure was $0. Sustained growth in long-term debt can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how abrdn Life Sciences Investors's long-term debt evolved across reporting periods, while the comparison chart places HQL next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.